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Although development of an effective AIDS vaccine to
provide sterilizing immunity remains an elusive goal, vac-
cine protection from disease progression has been
achieved in animal models, supporting this approach as a
realistic goal for first generation vaccines for humans. The
global epidemic would be expected to contract as long as
viral load could be durably sustained at levels below 2000
RNA copies/ml, a level at which the probability of trans-
mission and of disease progression are markedly reduced.
Such control occurs in a subset of infected persons, but the
immune responses in these persons have not been system-
atically defined. Here we examine HIV-specific cellular
and humoral immune function in persons who have
achieved such viral control without the need for medica-
tions, including those who maintain plasma virus below
the level of detection (< 50–75 copies/ml, aviremic con-
trollers, n = 64), persons with persistent low level viremia
(75–2000 copies, viremic controllers, n = 60) and persons
with chronic uncontrolled infection (n = 30). Results to
be presented indicate substantial individual heterogeneity
in adaptive immune responses among HIV controllers,
and none of the parameters tested predicts the ability to
contain virus. These results have important implications
for current HIV vaccine development strategies aimed at
durable maintenance of low level viremia.
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